The following relates to a dermal patch and more particularly to a dermal patch for delivering a pharmaceutical to a subject.
Typically, administration of a variety of pharmaceuticals, such as vaccines, is carried out via a multi-dose standard vial and syringe. In large majority, the delivery is intramuscular. This mode of administration requires the expertise of a medical professional, which can limit the availability of life-saving pharmaceuticals to certain patient populations. For example, in many developing areas of the world where access to medical professionals may be limited, such conventional modes of parenteral administration may deprive large segments of the population from access to needed pharmaceuticals.
Moreover, the multi-dose glass vial poses certain logistical and waste problems when used in large volumes for populations.
Furthermore, it has been found that intra-dermal or interstitial delivery of drugs including vaccines can have beneficial immunological effects as well as reduce the dose requirement. Fractional dosing is a key factor in creating affordability and in the case of pandemic response, rapid coverage of large patient volumes.
Aspects of the present disclosure address the above-referenced problems and/or others.
In one aspect, a method for delivery of a pharmaceutical to a subject is disclosed, which includes applying a dermal patch to a subject's skin, wherein the dermal patch comprises a reservoir that stores a pharmaceutical and further comprises at least one hollow needle configured for puncturing the skin, actuating the at least one needle to puncture the subject's skin, and causing at least a portion of the stored pharmaceutical to be released from the reservoir for delivery via a lumen of the hollow needle to the subject.
In some embodiments, the dermal patch can further include a fluidic channel that is configured to deliver the pharmaceutical released from said reservoir to the lumen of said hollow needle.
In some embodiments, the dermal patch is configured to be a single-use patch. In some such embodiments, the reservoir contains a quantity of the pharmaceutical that is suitable for a single-dose administration to the subject.
A dermal patch according to the present teachings can be used to administer, i.e., intra-dermally or intra-muscularly, a variety of different pharmaceuticals. By way of example, in some cases, the pharmaceutical can be a vaccine, though other pharmaceuticals including a variety of inoculating formulations and therapeutic formulation, can also be administered via a dermal patch according to the teachings.
In some embodiments, the at least one needle can be an array of hollow needles. In some embodiment the needle can have a length in a range of about 100 microns to about 1600 microns.
In some embodiments, the dermal patch includes a reservoir that includes a compressible membrane and the step of causing the release of said stored pharmaceutical comprises applying pressure to said compressible membrane to cause at least a portion of the pharmaceutical to exit the reservoir.
The subject can be any of a human and an animal (i.e., pets, horses, cows, etc.).
In a related aspect, a dermal patch for delivering a pharmaceutical to a subject includes a frame, which includes a reservoir that contains a pharmaceutical and at least one hollow needle movable from a retracted position to an extended position such that, when in the extended position, the needle is configured to puncture the subject's skin to provide a passageway via a lumen thereof for delivery of at least a portion of the pharmaceutical stored in said reservoir to the subject, and at least one actuator for actuating the needle to move the needle between the retracted position and the extended position. The dermal patch includes an adhesive layer that is coupled to the frame for attaching the dermal patch to the subject's skin. In some embodiments, a protective liner can cover an adhesive surface of the adhesive layer. In use, the protective liner can be removed to expose the adhesive surface of the adhesive layer for attaching the dermal patch to a patient's skin.
In some embodiments of the above dermal patch, said at least one actuator is further configured to cause release of the pharmaceutical from the reservoir. In some embodiments, the at least one actuator comprises two actuators one of which is configured for activating said needle to move the needle from the retracted position to the extended position for puncturing the skin and another one of said actuators is configured to cause release of the pharmaceutical from the reservoir.
In some embodiments of the above dermal patch, the reservoir can include a compressible membrane and said at least one actuator can include a sliding mechanism operably coupled to said compressible membrane such that the sliding mechanism can be moved to compress said membrane for releasing the pharmaceutical from the reservoir for delivery to the subject.
In some embodiments of the above dermal patch, said at least one actuator can include a pump coupled to the reservoir, where the pump is actuable by a user to cause release of the pharmaceutical from the reservoir.
The reservoir of the dermal patch can be prefilled with a variety of different pharmaceuticals. In some such embodiments, the pharmaceutical is a vaccine. By way of example, the volume of the pharmaceutical stored in the reservoir can be, for example, in a range of about 0.5 mL to about 2 mL.
In some embodiments, said at least one needle is configured for intra-dermal administration of a pharmaceutical while in other embodiments, said at least one needle is configured for intra-muscular administration of a pharmaceutical. By way of example, the length of the needle can be adjusted to allow for intra-dermal or intra-muscular administration of a pharmaceutical on board the dermal patch, i.e., a pharmaceutical with which the reservoir of the dermal patch is prefilled.
In some embodiments, the dermal patch can include a needle cartridge to which said at least one needle (which typically includes an array of needles) is coupled. In some such embodiments, the dermal patch further includes a mount (i.e., a mount that can be releasably disposed into an enclosure provided by the frame) to which the needle cartridge can mounted. The actuator of the dermal patch can be operably coupled to the mount to cause its movement so as to transition the one or more needles coupled to the mount from a retracted position to an extended position in which the needle(s) can puncture a subject's skin. For example, the actuator can include an actuating element that is operably coupled to the mount for causing movement thereof.
In some such embodiments, the dermal patch can include a biasing element (i.e., a spring) that is coupled to the mount to facilitate activating the mount so as to move the needle cartridge from an undeployed (retracted) position to a deployed (expanded) position. In some such embodiment, the biasing element can be a spring that is maintained in a compressed state via a latch such that upon release of the latch, the spring expands and releases the potential energy stored therein to cause the movement of the mount and hence the needle cartridge that mounted onto the mount.
The frame can include an opening provided in a lower wall thereof through which the needle cartridge can pass, upon activation of the needle cartridge, so as to allow the needle(s) access the subject's skin and puncture the skin for delivery of the pharmaceutical to the subject.
In one aspect, a method for intra-dermal delivery of a pharmaceutical to a subject, includes applying a dermal patch to a subject's skin, wherein the dermal patch comprises a reservoir that stores a pharmaceutical and further comprises at least one hollow needle configured for puncturing the skin, actuating the at least one needle to puncture the subject's skin, and causing at least a portion of the stored pharmaceutical to be released from the reservoir for delivery via a lumen of the hollow needle to the subject.
In another aspect, a dermal patch for delivering a pharmaceutical to a subject includes a frame including a sealed reservoir that contains a pharmaceutical, and at least one hollow needle movable from a retracted position to an extended position such that, when in the extended position, the needle is configured to puncture the subject's skin and deliver at least a portion of the pharmaceutical via a lumen of the hollow needle to the subject and an adhesive layer coupled to the frame for attaching the dermal patch to the subject's skin.
In yet another aspect, a method includes applying a dermal patch containing a pharmaceutical to a subject and delivering the pharmaceutical to the subject via the dermal patch.
In yet another aspect, a dermal patch for delivering a pharmaceutical to a subject includes a frame to which a sealed reservoir that holds a pharmaceutical and an array of hollow needles are coupled. The dermal patch can include at least one actuator for actuating the needles to puncture a subject's skin and further cause the release of the pharmaceutical from the sealed reservoir for delivery to the subject via lumens of the hollow needles. An adhesive layer coupled to at least a portion of the bottom surface of the frame (i.e., the surface facing the skin upon application of the dermal patch to the subject's skin) can allow attaching the dermal patch to the subject's skin.
Aspects of the present disclosure may take form in various components and arrangements of components, and in various steps and arrangements of steps. The drawings are only for illustration purpose of preferred embodiments of the present disclosure and are not to be considered as limiting.
Features of embodiments of the present disclosure will be more readily understood from the following detailed description take in conjunction with the accompanying drawings in which:
The present disclosure generally relates to a dermal patch for delivering a pharmaceutical (i.e., vaccines, medications, etc.) to a subject.
Some embodiments of the present disclosure include a dermal patch prefilled with a predetermined amount of a pharmaceutical for intradermal administration to a subject. As discussed in more detail below, in embodiments, such a dermal patch may include a reservoir in which a quantity of a pharmaceutical is stored. The dermal patch can also include a pharmaceutical delivery element for the administration of the pharmaceutical on board the dermal patch to a subject. In use, the dermal patch can be applied to the skin of a subject and the pharmaceutical delivery element can be actuated to puncture the skin to allow delivery of the pharmaceutical to the subject. As discussed in more detail below, in some such embodiments, the pharmaceutical delivery element can also cause release of the pharmaceutical from the reservoir in which the pharmaceutical is stored. In some other embodiments, the dermal patch can include a separate release element for causing the pharmaceutical to exit the reservoir and be delivered to the subject.
A dermal patch that delivers a predetermined quantity of a pharmaceutical to a subject can provide a number of advantages. For example, it can allow for the delivery of a pharmaceutical without a need for a highly trained medical professional. Further, it can allow for the delivery of a more accurate dose of a pharmaceutical to a subject, as the on-board pharmaceutical reservoir may be prefilled with a dose of the pharmaceutical more accurately than a standard syringe.
Further embodiments of the present disclosure include a dermal patch with retractable needles that deliver a pharmaceutical. Providing a dermal patch with retractable needles increases the safety of the dermal patch as the needles may only be exposed to an environment external to the dermal patch when delivering the pharmaceutical.
In some embodiments, the dermal patch is a single-use dermal patch. Stated another way, the dermal patch can be preconfigured to contain a single dose of a pharmaceutical and cannot be refilled after administration of the pharmaceutical to the subject. Providing a single-use dermal patch for administering a pharmaceutical, such as a vaccine, can reduce the risk of contamination between subjects.
Furthermore, the dermal patch can deliver the pharmaceutical intradermally. Providing a dermal patch that can deliver a pharmaceutical intradermally may reduce the cost of administering the pharmaceutical as less pharmaceutical may be needed (i.e., a fractional dose) when compared with standard intramuscular delivery systems (i.e., a vial and syringe system).
The terms “needle” and “microneedle” are used herein to broadly refer to an element that can provide a passageway, or facilitate the production of a passageway, for administering a pharmaceutical (i.e., vaccine, medication, etc.) through a subject's skin (i.e., by puncturing the subject's skin.
The terms “pharmaceutical” and “pharmaceutical formulation” as used herein refers to any formulation used in the treatment of a medical condition. Pharmaceuticals include, but are not limited to, vaccines (i.e., bacterial vaccines, viral vaccines, mRNA vaccines, etc.) and medications that may be delivered via an injection.
The term “subject” as used herein refers to a human subject or an animal subject (i.e., chicken, pig, cattle, dog, cat, etc.).
As used herein, the term “about” means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 100 μm means in the range of 90 μm-110 μm.
As used herein a “longitudinal” direction is a direction that is substantially orthogonal to a bottom wall of a frame a dermal patch.
As used herein, a “horizontal” direction is a direction that is substantially parallel to a bottom wall of a frame of a dermal patch.
While the following describes a dermal patch for intradermal administration of a pharmaceutical to a subject, in other embodiments, the dermal patch may be modified by changing the needles of the dermal patch (i.e., by providing a dermal patch with longer needles) such that the dermal patch is capable of delivering a pharmaceutical to a subject via an intramuscular injection.
Referring now to
Referring now to
The frame 200 includes a bottom wall 202 having an inner surface 202a and an outer surface 202b opposite the inner surface 202a, which faces a subject's skin upon application of the dermal patch to the subject's skin. The bottom wall 202 defines an aperture 204 that extends between the inner surface 202a and the outer surface 202b and through which an array of hollow needles can pass, when actuated, to puncture the skin and allow the administration of the pharmaceutical on board the patch via the lumens of the hollow needles through the skin punctured by those needles.
With particular reference to
The frame 200 further includes a peripheral wall 206 that extends longitudinally from and perpendicular to the bottom wall 202. The peripheral wall 206 includes an inner surface 206a and an outer surface 206b opposite the inner surface 206b. The peripheral wall 206 further includes a top surface 206c, which extends horizontally between the inner surface 206a and the outer surface 206b.
With particular reference to
The inner wall 210 includes an inner surface 210a and a substantially cylindrical outer surface 210b opposite the inner surface 210a. While the inner wall 210 is depicted as being cylindrical, in other embodiments the inner wall 210 may have a different shape. The inner wall 210 further includes a plurality of vertical grooves 214 that are formed in the outer surface 210b. The grooves 214 extend longitudinally from the bottom wall 202 to the top wall 212.
The top wall 212 includes a top surface 212a and a bottom surface 212b opposite the top surface 212a. A curved rim 216 extends between the top surface 212a and the bottom surface 212b. The curved rim 216 includes a plurality of sections 216a that are separated by a plurality of segments 216b of the curved rim 216. The sections 216a define a plurality of recesses 218 and the segments 216b define an opening 220. The opening 220 is shaped and dimensioned to accommodate a mount to which an array of hollow needles is mounted, as discussed in more detail below. Further, as discussed in more detail below, the mount can include a plurality of latches that can engage with the sections 216a of the curved rim 216. The inner surface 210a of the inner wall 210 and the bottom surface 212b of the top wall 212 define an inner volume 222 of the frame 200. As will be discussed in further detailed herein the inner volume 222 is shaped and dimensioned to accommodate the mount with the needle array. While the top wall 212 is depicted as an element of the frame 200, in other embodiments, the top wall 212 may be part of the actuator 300. Furthermore, the top wall 212 may be moveable and may be detached from the frame 200.
With particular reference to
As depicted in
The actuator 300 further includes a plurality of latches 310. The latches 310 extend longitudinally from and perpendicular to the bottom surface 304b of the top wall 304.
While
The dermal patch 100 further includes a mount 500 that can be releasably placed in the enclosure 208. The mount 500 includes a bottom wall 502 and a peripheral wall 504 that extends longitudinally from and perpendicular to the bottom wall 502.
The bottom wall 502 includes a top surface 502a, a bottom surface 502b opposite the top surface 502a, and an outer surface 502c that extends longitudinally between and perpendicular to the top surface 502a and the bottom surface 502b. The outer surface 502c is cylindrical in shape and contacts the inner surface 210a of the inner wall 210 when the mount 500 is installed within the enclosure 208. Stated another way, the bottom wall 502 is shaped such that the mount 500 fits within the inner volume 222. The bottom wall 502 forms a recess 506 which is configured to receive a needle cartridge 700 that includes a plurality of hollow needles 704. While the needle cartridge 700 is depicted as being circular, in other embodiments the needle cartridge may have a different shape.
The peripheral wall 504 includes an inner surface 504a, an outer surface 504b opposite the inner surface, and a top surface 504c that extends between the inner surface 504a and the outer surface 504b. The inner surface 504a defines an inner volume 508.
The mount 500 further includes a piercing element 510. While mount 500 is depicted as including one piercing element 510, in other embodiments the mount 510 may include a plurality of piercing elements 510. The piercing element 510 extends longitudinally from the bottom wall 502. The piercing element 510 includes a sharp point that aids in delivering a pharmaceutical to a subject. The mount 500 includes an opening 512 that is in fluid communication with a plurality of microfluidic channels 514 that are formed in the bottom surface 502b of the bottom wall 502 and extend radially from the opening 512 to connect to lumens of a plurality of hollow needles when needles are mounted onto the mount 500. The microfluidic channels 514 may have a depth of 200 to 500 microns.
The mount 500 further includes a plurality of latches 516 that extend longitudinally from and perpendicular to the base bottom wall 502, which can engage with the sections 216a of the curved rim 216.
The dermal patch 100 further includes a sealed reservoir 600 that is prefilled with a pharmaceutical. In one embodiment the reservoir 600 is in the form of a blister pack. In another embodiment, the reservoir 600 is a blow-fill-sealed reservoir. The reservoir 600 is dimensioned and shaped to fit within the inner volume 508 of the mount 500. The reservoir 600 is sealed by a frangible membrane 602 and retains a quantity of a pharmaceutical In some embodiments, the reservoir 600 is pre-filled with a predetermined quantity of a pharmaceutical that is sufficient for the administration of a single dose of the pharmaceutical to the subject.
The dermal patch 100 further includes a needle cartridge 700. In this embodiment, the needle cartridge 700 can be received in the recess 506 of the mount.
In this embodiment, the needle cartridge 700 includes a platform 702 to which a plurality of needles 704 is coupled. The platform 702 is shaped as a disk having a top surface 702a, an opposed bottom surface 702b, and a peripheral surface 702c that extends longitudinally between the top surface 702a and the bottom surface 702b. When coupled to the mount 500, the top surface 702a of the platform 702 couples to the bottom surface 502b of the bottom wall 502.
Once the needle cartridge is coupled to the mount 500, the upper surface of the cartridge and the microfluidic channels formed in the lower surface of the mount 500 form fluidic passages through which the pharmaceutical released from the reservoir 600 can be delivered to the lumen of hollow needles 704 for delivery to a subject.
The hollow needles 704 are configured to puncture the skin of a subject and deliver a pharmaceutical to the subject. While the dermal patch 100 is depicted as including 12 needles, in other embodiments, the dermal patch may include a different number of needles (i.e., 1, 7, 15, 20, etc.). Furthermore, while the needles 704 are depicted as arranged in a circular pattern around the circumference of the platform 702, in other embodiments the needles 704 may be arranged in a different pattern (i.e., in a linear pattern, in a checkerboard pattern, in a semi-circular pattern, etc.).
In some embodiments, the needles 704 are microneedles are about 100 microns to about 1600 microns in length, about 50 to about 250 microns in width, and about 1-25 microns in diameter, though other sizes may also be employed. For example, when the dermal patch is configured for intradermal administration of a pharmaceutical, the needles can have a length in a range of about 100 microns to about 800 microns. In other embodiments in which the needles are configured for intramuscular administration of a pharmaceutical, the needles can have a length in a range of about 800 microns to 1600 microns, though any other suitable lengths for intra-dermal or intra-muscular administration can also be employed.
The bottom wall 502 and therefore the needle cartridge 700 is in register with the aperture 204 of the frame 200. As will be discussed in further detail herein, the mount 500 is moveable such that the needle cartridge 700 extends through the aperture 204.
The dermal patch 500 further includes a pin 800. The pin 800 includes a base 802, an outer wall 804. The base 802 includes a top surface 802a, a bottom surface 802b opposite the top surface 802a, and an outer surface 804c that extends longitudinally between and perpendicular to the top surface 802a and the bottom surface 802b. The outer surface 802c is cylindrical in shape and contacts the inner surface 504a of the peripheral wall 504 when the pin 800 is installed within the mount 500. Stated another way, the base 802 is shaped such that the pin 800 fits within the inner volume 508 of mount 500.
The outer wall 804 extends longitudinally from and perpendicular to the base 802. The outer wall 804 and the base 802 have the same circumference. The outer wall 804 has an inner surface 804a and an outer surface 804b. When the pin 800 is installed in the mount 500, the outer surface 804b contacts the inner surface 504a of the peripheral wall 504.
The pin 800 further includes a plurality of latches 806. The plurality of latches 806 extend longitudinally from and perpendicular to the base 802.
The dermal patch 100 further includes a first biasing element (or a first spring) 902 and a second biasing element (or a second spring) 904.
The first biasing element 902 biasing element is disposed circumferentially about the inner wall 210 of the enclosure 208. The first biasing element includes a top end 902a and an opposed bottom end 902b. The top end 902a contacts the bottom surface 212b of the top wall 212 of the frame 200 and the bottom end 902b contacts the top surface 502a of the bottom wall 502 of the mount 500. Stated another way, the first biasing element 902 extends longitudinally between the bottom surface 212b of the top wall 212 and the top surface 502a of the bottom wall 502.
The second biasing element 904 extends horizontally between opposing sides of the inner surface 804a of the outer wall 804 and between latches 806 of the pin 800. The inner surface 804a and the latches 806 retain the second biasing element 904. The second biasing element 904 includes a top end 904a and a bottom end 904b. The top end 904a contacts the bottom surface 304b of the top wall 304 of the actuator 300. The bottom end 904b contacts the top surface 802a of the base 802 of the pin 800.
In use, the dermal patch 100 can be adhered to the skin of a subject via the adhesive layer 400. Once the dermal patch 100 has been applied to a subject's skin, the dermal patch 100 may be used to deliver a pharmaceutical to the subject. Initially, as depicted in
In the retracted position, the needles 702 are not able to puncture skin of the subject. In the undeployed position the first biasing element 902 is in a compressed state relative to its natural state. In this state, the first biasing element 902 has an elastic potential energy as a result of this deformation.
The latches 516 of the mount 500 and the latches 310 of the actuator 300 and retain the mount 500 in the undeployed position. In the undeployed position, the ends of the latches 310 extend through the opening 508 of the frame 200 and press the ends of the latches 516 into the top wall 212 such that the ends of the latches 516 hook to the top surface 212a of the top wall 212 of the frame 200. This force is greater than the elastic potential energy of the first biasing element 902 thereby preventing the first biasing element 902 from expanding and moving the mount 500.
As depicted in
While
When the actuator 300 is in the undeployed position and the deployed needle position, the pin 800 is in an undeployed position. In this position, the pin 800 is not able to contact the reservoir 600. In the undeployed position the second biasing element 904 is in a compressed state relative to its natural state. In this state, the second biasing element 904 has an elastic potential energy as a result of this deformation. The latches 806 of the pin 800 retain the pin 800 in the undeployed position. In the undeployed position, ends of the latches 806 extend through the openings 308 and hook to the top surface 304a of the top wall 304 of the actuator 300. A component of the actuator 300 presses the latches 800 into the top wall 304 with a force that is greater than the elastic potential energy of the second biasing element 904 thereby preventing the second biasing element from expanding and moving the pin 800.
As depicted in
In the deployed position, the bottom surface 802b contacts the reservoir 600. The pin 800 compresses the sealed reservoir into the piercing element 510. When compressed into the piercing element 510, the reservoir 600 ruptures and the pharmaceutical stored in the reservoir 600 flow into opening 512. Since the opening 512 is in fluid communication with each of the microfluidic channels 514 which are each in communication with a needle 704, the pharmaceutical flows through the opening 512 and each of the microfluidic channels 514 and is delivered to the subject via a needle 704. While the pharmaceutical is being delivered to the subject, the first biasing element applies a continuous force to the mount 500 thereby ensuring the needles 704 stay within the skin of the subject during pharmaceutical delivery.
In some embodiments, after the pharmaceutical has been administered, the mount 500 may be retracted into the inner volume 222 of the frame 200 such that the needles 704 are removed from the subject and are completely disposed within the inner volume 222. In one embodiment, the mount 500 may be retracted by rotating or pulling the actuator 300 to retract the needles 704.
After the pharmaceutical has been delivered, the dermal patch 100 may be removed from the subject by peeling the dermal patch 100 off of the subject's skin.
Referring now to
In this embodiment, the dermal patch 1000 includes a slidable pharmaceutical reservoir 1002 and the frame 200 is modified to support the slidable pharmaceutical reservoir 1002. The slidable pharmaceutical reservoir 1002 includes a sealed reservoir 1004, a push tab 1006, and a puncture element receiving chamber 1008. In another embodiment, as depicted in
The sealed reservoir 1004 may be in the form of a blister pack as previously discussed with reference to the reservoir 600. That is, the sealed reservoir 1004 retains a pharmaceutical. In some embodiments, the sealed reservoir 1004 is prefilled with a predetermined amount of a pharmaceutical. In such embodiments, the predetermined quantity of the pharmaceutical formulation is configured to provides a single dose of the pharmaceutical administration to a subject.
The push tab 1006 is configured to allow a user to hold the push tab 1006 in order to move the slidable pharmaceutical reservoir 1002 from an undeployed position (
In this embodiment, the frame 200 further includes a hollow puncturing element 1010 and the puncture element receiving 1008 is shaped to receive the hollow puncturing element 1010. The hollow puncturing element 1010 includes a protrusion 1012 that extends circumferentially around an outer wall of the hollow puncturing element 1010 and the puncture element receiving chamber 1008 includes a first groove 1014 and a second groove 1016 that extend circumferentially within the puncture element receiving chamber 1008. The first groove 1014 receives the protrusion 1012 when the slidable pharmaceutical reservoir 1002 is in the undeployed position and the second groove 1016 receives protrusion 1012 when the slidable pharmaceutical reservoir 1002 is in the deployed position.
The hollow puncturing element 1010 includes a hollow point 1018 for puncturing the sealed reservoir 1004 and a microfluidic channel 1020 in communication with the hollow point 1018. The microfluidic channel 1020 is in communication with the plurality of secondary microfluidic channels. As such, the microfluidic channel 1020 is in communication with each needle 704.
In use, the dermal patch 1000 is adhered to the skin of a subject as previously discussed herein with respect to the dermal patch 100. Initially, as depicted in
Referring now to
The vial chamber 1102 is dimensioned and shaped for receiving a vial 1106 that contains a pharmaceutical. The vial 1106 is sealed by a frangible membrane 1108. The mount chamber 1106 is shaped and dimensioned for retaining the mount 500.
The housing 1102 further includes a hollow puncturing element 1110. The hollow puncturing element 1110 includes a point 1112 for puncturing the membrane 1108 of the vial 1106. The housing 1102 further includes a microfluidic channel 1114 that is in communication with the point 1112. The microfluidic channel 1114 is also in communication with the plurality of microfluidic channels 514. As such, the microfluidic channel 1114 is in communication with each needle 704.
In use, the dermal patch 1100 is adhered to the skin of a subject as previously discussed herein with respect to the dermal patch 100. As depicted in
The frame 200, the actuator 300, the mount 500, needle cartridge 700, the pin 800, and the housing 1100 may be formed from polymeric materials including, but not limited to, polymeric materials, i.e., polyolefins, PET (Polyethylene Terephthalate), polyurethanes, polynorbornenes, polyethers, polyacrylates, polyamides (Polyether block amide also referred to as Pebax®), polysiloxanes, polyether amides, polyether esters, trans-polyisoprenes, polymethyl methacrylates (PMMA), cross-linked trans-polyoctylenes, cross-linked polyethylenes, cross-linked polyisoprenes, cross-linked polycyclooctenes, inorganic-organic hybrid polymers, co-polymer blends with polyethylene and Kraton®, styrene-butadiene co-polymers, urethane-butadiene co-polymers, polycaprolactone or oligo caprolactone co-polymers, polylactic acid (PLLA) or polylactide (PL/DLA) co-polymers, PLLA-polyglycolic acid (PGA) co-polymers, and photocrosslinkable polymer. The slidable pharmaceutical reservoir 1002 may be formed of a plastic, aluminum or a combination thereof.
While the invention has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive; embodiments of the present disclosure are not limited to the disclosed embodiments. Other variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing embodiments of the present disclosure, from a study of the drawings, the disclosure, and the appended claims.
In the claims, the word “comprising” does not exclude other elements or steps, and the indefinite article “a” or “an” does not exclude a plurality. A single processor or other processing unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measured cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.
Number | Name | Date | Kind |
---|---|---|---|
5015228 | Columbus et al. | May 1991 | A |
5338308 | Wilk | Aug 1994 | A |
5441490 | Svedman | Aug 1995 | A |
5527288 | Gross et al. | Jun 1996 | A |
5602037 | Ostgaard et al. | Feb 1997 | A |
5636640 | Staehlin | Jun 1997 | A |
5680872 | Sesekura et al. | Oct 1997 | A |
5848991 | Gross et al. | Dec 1998 | A |
5997501 | Gross | Dec 1999 | A |
6234980 | Bell | May 2001 | B1 |
6315985 | Wu et al. | Nov 2001 | B1 |
6454140 | Jinks | Sep 2002 | B1 |
6500150 | Gross et al. | Dec 2002 | B1 |
6506168 | Fathallah et al. | Jan 2003 | B1 |
6524284 | Marshall | Feb 2003 | B1 |
6610273 | Wu et al. | Aug 2003 | B2 |
6623457 | Rosenberg | Sep 2003 | B1 |
6644517 | Thiel et al. | Nov 2003 | B2 |
6689118 | Alchas et al. | Feb 2004 | B2 |
6776776 | Alchas et al. | Aug 2004 | B2 |
6780171 | Gabel et al. | Aug 2004 | B2 |
6796429 | Cameron et al. | Sep 2004 | B2 |
6808506 | Lastovich et al. | Oct 2004 | B2 |
6893655 | Flanigan et al. | May 2005 | B2 |
6932082 | Stein | Aug 2005 | B2 |
6960193 | Rosenberg | Nov 2005 | B2 |
6994691 | Ejlersen | Feb 2006 | B2 |
7004928 | Aceti et al. | Feb 2006 | B2 |
7083592 | Lastovich et al. | Aug 2006 | B2 |
7101534 | Schultz et al. | Sep 2006 | B1 |
7156838 | Gabel et al. | Jan 2007 | B2 |
7175642 | Briggs et al. | Feb 2007 | B2 |
7182955 | Hart et al. | Feb 2007 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7252651 | Haider et al. | Aug 2007 | B2 |
7282058 | Levin et al. | Oct 2007 | B2 |
7308893 | Boot | Dec 2007 | B2 |
7435415 | Gelber | Oct 2008 | B2 |
7637891 | Wall | Dec 2009 | B2 |
7651475 | Angel et al. | Jan 2010 | B2 |
7678079 | Shermer et al. | Mar 2010 | B2 |
7846488 | Johnson et al. | Dec 2010 | B2 |
7905866 | Haider et al. | Mar 2011 | B2 |
8048019 | Nisato et al. | Nov 2011 | B2 |
8057842 | Choi et al. | Nov 2011 | B2 |
8066680 | Alchas et al. | Nov 2011 | B2 |
8079960 | Briggs et al. | Dec 2011 | B2 |
8104469 | Dams | Jan 2012 | B2 |
8108023 | Mir et al. | Jan 2012 | B2 |
8157768 | Haider et al. | Apr 2012 | B2 |
8206336 | Shantha | Jun 2012 | B2 |
8246582 | Angel et al. | Aug 2012 | B2 |
8246893 | Ferguson et al. | Aug 2012 | B2 |
8252268 | Slowey et al. | Aug 2012 | B2 |
8267889 | Cantor et al. | Sep 2012 | B2 |
8303518 | Aceti et al. | Nov 2012 | B2 |
D681195 | Skulley et al. | Apr 2013 | S |
8409140 | Ejlersen et al. | Apr 2013 | B2 |
8414503 | Briggs et al. | Apr 2013 | B2 |
8414959 | Hye-Ok et al. | Apr 2013 | B2 |
8430097 | Jinks et al. | Apr 2013 | B2 |
8459253 | Howgill | Jun 2013 | B2 |
8491500 | Briggs et al. | Jul 2013 | B2 |
8496601 | Briggs et al. | Jul 2013 | B2 |
D687550 | Moeckly et al. | Aug 2013 | S |
D687551 | Moeckly et al. | Aug 2013 | S |
D687945 | Brewer et al. | Aug 2013 | S |
D687946 | Brewer et al. | Aug 2013 | S |
D687947 | Brewer et al. | Aug 2013 | S |
8512244 | Jennewine | Aug 2013 | B2 |
8517019 | Brewer et al. | Aug 2013 | B2 |
8554317 | Duan | Oct 2013 | B2 |
8556861 | Tsals | Oct 2013 | B2 |
8561795 | Schott | Oct 2013 | B2 |
D693921 | Burton et al. | Nov 2013 | S |
8602271 | Winker et al. | Dec 2013 | B2 |
8603040 | Haider et al. | Dec 2013 | B2 |
8608889 | Sever et al. | Dec 2013 | B2 |
8622963 | Iwase et al. | Jan 2014 | B2 |
8696619 | Schnall | Apr 2014 | B2 |
8696637 | Ross | Apr 2014 | B2 |
D705422 | Burton et al. | May 2014 | S |
8715232 | Yodfat et al. | May 2014 | B2 |
8740014 | Purkins et al. | Jun 2014 | B2 |
8741377 | Choi et al. | Jun 2014 | B2 |
8784363 | Frederickson et al. | Jul 2014 | B2 |
8808202 | Brancazio | Aug 2014 | B2 |
8808786 | Jinks et al. | Aug 2014 | B2 |
8814009 | Hodson et al. | Aug 2014 | B2 |
8814035 | Stuart | Aug 2014 | B2 |
8821412 | Gonzalez-Zugasti et al. | Sep 2014 | B2 |
8821446 | Trautman et al. | Sep 2014 | B2 |
8821779 | Ferguson et al. | Sep 2014 | B2 |
8827971 | Gonzalez-Zugasti et al. | Sep 2014 | B2 |
8870821 | Laufer | Oct 2014 | B2 |
8900180 | Wolter et al. | Dec 2014 | B2 |
8900194 | Clarke et al. | Dec 2014 | B2 |
8945071 | Christensen | Feb 2015 | B2 |
8961431 | Roe et al. | Feb 2015 | B2 |
9022973 | Sexton et al. | May 2015 | B2 |
9033898 | Chickering, III et al. | May 2015 | B2 |
9041541 | Levinson et al. | May 2015 | B2 |
D733290 | Burton et al. | Jun 2015 | S |
9067031 | Jinks et al. | Jun 2015 | B2 |
9072664 | Stein et al. | Jul 2015 | B2 |
9089661 | Stuart et al. | Jul 2015 | B2 |
9089677 | Soo et al. | Jul 2015 | B2 |
9113836 | Bernstein et al. | Aug 2015 | B2 |
9119578 | Haghgooie et al. | Sep 2015 | B2 |
9119945 | Simons et al. | Sep 2015 | B2 |
9133024 | Phan et al. | Sep 2015 | B2 |
9144651 | Stuart | Sep 2015 | B2 |
9144671 | Cantor et al. | Sep 2015 | B2 |
9173994 | Ziaie et al. | Nov 2015 | B2 |
9174035 | Ringsred et al. | Nov 2015 | B2 |
9186097 | Frey et al. | Nov 2015 | B2 |
9227021 | Buss | Jan 2016 | B2 |
9289763 | Berthier et al. | Mar 2016 | B2 |
9289925 | Ferguson et al. | Mar 2016 | B2 |
9289968 | Sever et al. | Mar 2016 | B2 |
9295417 | Haghgooie et al. | Mar 2016 | B2 |
9295987 | Kelly et al. | Mar 2016 | B2 |
9339956 | Rendon | May 2016 | B2 |
9380972 | Fletcher et al. | Jul 2016 | B2 |
9380973 | Fletcher et al. | Jul 2016 | B2 |
9468404 | Hayden | Oct 2016 | B2 |
9480428 | Colin et al. | Nov 2016 | B2 |
9504813 | Buss | Nov 2016 | B2 |
9522225 | Chong et al. | Dec 2016 | B2 |
9549700 | Fletcher et al. | Jan 2017 | B2 |
9555187 | Sonderegger et al. | Jan 2017 | B2 |
9566393 | Iwase et al. | Feb 2017 | B2 |
9579461 | Sonderegger et al. | Feb 2017 | B2 |
9623087 | Zhang et al. | Apr 2017 | B2 |
9642895 | Dai et al. | May 2017 | B2 |
9643229 | Wilson et al. | May 2017 | B2 |
9675675 | Zhang et al. | Jun 2017 | B2 |
9675752 | Christensen | Jun 2017 | B2 |
9682222 | Burton et al. | Jun 2017 | B2 |
9693950 | Determan et al. | Jul 2017 | B2 |
9694149 | Jinks et al. | Jul 2017 | B2 |
9717850 | Sonderegger | Aug 2017 | B2 |
9724462 | Rotem | Aug 2017 | B2 |
9730624 | Gonzalez-Zugasti et al. | Aug 2017 | B2 |
9770578 | Chowdhury | Sep 2017 | B2 |
9775551 | Bernstein et al. | Oct 2017 | B2 |
9782574 | Simmers | Oct 2017 | B2 |
9789249 | Frederickson et al. | Oct 2017 | B2 |
9789299 | Simmers | Oct 2017 | B2 |
9844631 | Bureau | Dec 2017 | B2 |
9849270 | Stockholm | Dec 2017 | B2 |
D808515 | Atkin et al. | Jan 2018 | S |
9861580 | Mueting et al. | Jan 2018 | B2 |
9861801 | Baker et al. | Jan 2018 | B2 |
9872975 | Burton et al. | Jan 2018 | B2 |
9884151 | Sullivan et al. | Feb 2018 | B2 |
9895520 | Burton et al. | Feb 2018 | B2 |
9956170 | Cantor et al. | May 2018 | B2 |
9968767 | Hasan et al. | May 2018 | B1 |
9987629 | Berthier et al. | Jun 2018 | B2 |
9993189 | Phan et al. | Jun 2018 | B2 |
10004887 | Gross et al. | Jun 2018 | B2 |
10010676 | Bureau | Jul 2018 | B2 |
10010706 | Gonzalez et al. | Jul 2018 | B2 |
10010707 | Colburn et al. | Jul 2018 | B2 |
10016315 | Letourneau et al. | Jul 2018 | B2 |
10029845 | Jinks | Jul 2018 | B2 |
10035008 | Brandwein et al. | Jul 2018 | B2 |
10076649 | Gilbert et al. | Sep 2018 | B2 |
10080843 | Bureau | Sep 2018 | B2 |
10080846 | Sonderegger et al. | Sep 2018 | B2 |
10099043 | Berry et al. | Oct 2018 | B2 |
10105524 | Meyer et al. | Oct 2018 | B2 |
10111807 | Baker et al. | Oct 2018 | B2 |
D834704 | Atkin et al. | Nov 2018 | S |
10154957 | Zhang et al. | Dec 2018 | B2 |
10155334 | Rendon | Dec 2018 | B2 |
10183156 | Ross et al. | Jan 2019 | B2 |
10188335 | Haghgooie et al. | Jan 2019 | B2 |
D840020 | Howgill | Feb 2019 | S |
10201691 | Berry et al. | Feb 2019 | B2 |
10232157 | Berry et al. | Mar 2019 | B2 |
10232160 | Baker et al. | Mar 2019 | B2 |
10248765 | Holmes et al. | Apr 2019 | B1 |
10265484 | Stuart et al. | Apr 2019 | B2 |
10272214 | Child et al. | Apr 2019 | B2 |
10300260 | Wirtanen et al. | May 2019 | B2 |
10307578 | Frederickson et al. | Jun 2019 | B2 |
10315021 | Frederickson et al. | Jun 2019 | B2 |
10327990 | Egeland et al. | Jun 2019 | B2 |
10328248 | Baker et al. | Jun 2019 | B2 |
10335560 | Stein et al. | Jul 2019 | B2 |
10335562 | Jinks et al. | Jul 2019 | B2 |
10335563 | Brewer et al. | Jul 2019 | B2 |
10357610 | Sonderegger | Jul 2019 | B2 |
10384047 | Simmers | Aug 2019 | B2 |
10391290 | Burton et al. | Aug 2019 | B2 |
10398885 | Frits et al. | Sep 2019 | B2 |
10406339 | Simmers | Sep 2019 | B2 |
10410838 | Hanson et al. | Sep 2019 | B2 |
10426390 | Berthier et al. | Oct 2019 | B2 |
10426739 | Knutson | Oct 2019 | B2 |
10478346 | Knutson | Nov 2019 | B2 |
10492716 | Berthier et al. | Dec 2019 | B2 |
10507286 | Egeland et al. | Dec 2019 | B2 |
10518071 | Kulkarni | Dec 2019 | B2 |
D872853 | Stuart et al. | Jan 2020 | S |
10525463 | Kelly et al. | Jan 2020 | B2 |
10542922 | Sia et al. | Jan 2020 | B2 |
10543310 | Bernstein et al. | Jan 2020 | B2 |
10549079 | Burton et al. | Feb 2020 | B2 |
10568937 | Hattersley et al. | Feb 2020 | B2 |
D878544 | Stuart et al. | Mar 2020 | S |
10576257 | Berry et al. | Mar 2020 | B2 |
10596333 | Howgill | Mar 2020 | B2 |
10598583 | Peeters et al. | Mar 2020 | B1 |
10638963 | Beyerlein et al. | May 2020 | B2 |
10646703 | Chowdhury | May 2020 | B2 |
10653349 | Delamarche et al. | May 2020 | B2 |
10695289 | Brown et al. | Jun 2020 | B2 |
10695547 | Burton et al. | Jun 2020 | B2 |
10716926 | Burton et al. | Jul 2020 | B2 |
10729842 | Hooven | Aug 2020 | B2 |
10772550 | Aceti et al. | Sep 2020 | B2 |
10779757 | Berthier et al. | Sep 2020 | B2 |
10799166 | Gonzalez-Zugasti et al. | Oct 2020 | B2 |
10835163 | Haghgooie et al. | Nov 2020 | B2 |
10881342 | Kelly et al. | Jan 2021 | B2 |
10888259 | Jordan et al. | Jan 2021 | B2 |
10926030 | Lanigan et al. | Feb 2021 | B2 |
10932710 | Jordan et al. | Mar 2021 | B2 |
10939860 | Levinson et al. | Mar 2021 | B2 |
10940085 | Baker et al. | Mar 2021 | B2 |
10953211 | Ross et al. | Mar 2021 | B2 |
11020548 | Stuart et al. | Jun 2021 | B2 |
11033212 | Berthier et al. | Jun 2021 | B2 |
11040183 | Baker et al. | Jun 2021 | B2 |
11103685 | Gonzalez et al. | Aug 2021 | B2 |
11110234 | Richardson et al. | Sep 2021 | B2 |
11116953 | Kobayashi et al. | Sep 2021 | B2 |
11147955 | Gross et al. | Oct 2021 | B2 |
11177029 | Levinson et al. | Nov 2021 | B2 |
11197625 | Schleicher et al. | Dec 2021 | B1 |
11202895 | Davis et al. | Dec 2021 | B2 |
11207477 | Hodson | Dec 2021 | B2 |
11247033 | Baker et al. | Feb 2022 | B2 |
11253179 | Bernstein et al. | Feb 2022 | B2 |
11266337 | Jackson et al. | Mar 2022 | B2 |
11273272 | Stuart et al. | Mar 2022 | B2 |
11291989 | Morrison | Apr 2022 | B2 |
11298060 | Jordan et al. | Apr 2022 | B2 |
11298478 | Stuart et al. | Apr 2022 | B2 |
11304632 | Mou et al. | Apr 2022 | B2 |
11344684 | Richardson et al. | May 2022 | B2 |
11395614 | Berthier et al. | Jul 2022 | B2 |
11452474 | Nawana et al. | Sep 2022 | B1 |
11458289 | Moeckly et al. | Oct 2022 | B2 |
11497712 | Stein et al. | Nov 2022 | B2 |
11497866 | Howgill | Nov 2022 | B2 |
11510602 | Nawana et al. | Nov 2022 | B1 |
20020077584 | Lin et al. | Jun 2002 | A1 |
20020193740 | Alchas et al. | Dec 2002 | A1 |
20040002121 | Regan et al. | Jan 2004 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040059256 | Perez | Mar 2004 | A1 |
20040059366 | Sato et al. | Mar 2004 | A1 |
20040106904 | Gonnelli et al. | Jun 2004 | A1 |
20040162467 | Cook | Aug 2004 | A1 |
20050106713 | Phan et al. | May 2005 | A1 |
20050118388 | Kingsford | Jun 2005 | A1 |
20060047243 | Rosenberg | Mar 2006 | A1 |
20060068490 | Tang et al. | Mar 2006 | A1 |
20060142651 | Brister et al. | Jun 2006 | A1 |
20070004989 | Dhillon | Jan 2007 | A1 |
20070191696 | Mischler et al. | Aug 2007 | A1 |
20080003274 | Kaiser | Jan 2008 | A1 |
20080287864 | Rosenberg | Nov 2008 | A1 |
20090012472 | Ahm et al. | Jan 2009 | A1 |
20090036826 | Sage, Jr. et al. | Feb 2009 | A1 |
20090099427 | Jina et al. | Apr 2009 | A1 |
20090112125 | Tamir | Apr 2009 | A1 |
20090198215 | Chong et al. | Aug 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20100198107 | Groll et al. | Aug 2010 | A1 |
20100249560 | Levinson et al. | Sep 2010 | A1 |
20100256524 | Levinson et al. | Oct 2010 | A1 |
20100269837 | Levinson et al. | Oct 2010 | A1 |
20100272652 | Levinson | Oct 2010 | A1 |
20110009847 | Levinson et al. | Jan 2011 | A1 |
20110060280 | Caffey et al. | Mar 2011 | A1 |
20110105872 | Chickering, III et al. | May 2011 | A1 |
20110105951 | Bernstein et al. | May 2011 | A1 |
20110105952 | Bernstein et al. | May 2011 | A1 |
20110125058 | Levinson et al. | May 2011 | A1 |
20110144463 | Pesach et al. | Jun 2011 | A1 |
20110172508 | Chickering, III et al. | Jul 2011 | A1 |
20110172510 | Chickering, III et al. | Jul 2011 | A1 |
20110198221 | Angelescu | Aug 2011 | A1 |
20110213335 | Burton et al. | Sep 2011 | A1 |
20110245635 | Fujiwara et al. | Oct 2011 | A1 |
20110257497 | Tamada et al. | Oct 2011 | A1 |
20110288389 | Levinson et al. | Nov 2011 | A9 |
20120016308 | Schott | Jan 2012 | A1 |
20120041338 | Chickering et al. | Feb 2012 | A1 |
20120046203 | Walsh et al. | Feb 2012 | A1 |
20120078224 | Lerner et al. | Mar 2012 | A1 |
20120109066 | Chase et al. | May 2012 | A1 |
20120123297 | Brancazio | May 2012 | A1 |
20120259599 | Deck et al. | Oct 2012 | A1 |
20120271123 | Castle et al. | Oct 2012 | A1 |
20120271125 | Bernstein et al. | Oct 2012 | A1 |
20120275955 | Haghgooie et al. | Nov 2012 | A1 |
20120277629 | Bernstein et al. | Nov 2012 | A1 |
20120277696 | Gonzalez-Zugasti et al. | Nov 2012 | A1 |
20120277697 | Haghgooie et al. | Nov 2012 | A1 |
20130018279 | Plante et al. | Jan 2013 | A1 |
20130158468 | Bernstein et al. | Jun 2013 | A1 |
20130158482 | Davis et al. | Jun 2013 | A1 |
20130211289 | Moga et al. | Aug 2013 | A1 |
20130253446 | Duan et al. | Sep 2013 | A1 |
20130269423 | Angelescu | Oct 2013 | A1 |
20140066843 | Zhang et al. | Mar 2014 | A1 |
20140109900 | Jinks | Apr 2014 | A1 |
20140194854 | Tsals | Jul 2014 | A1 |
20140305823 | Gelfand et al. | Oct 2014 | A1 |
20140309555 | Gelfand et al. | Oct 2014 | A1 |
20140309557 | Fletcher et al. | Oct 2014 | A1 |
20140336616 | Edwards | Nov 2014 | A1 |
20150057510 | Levinson et al. | Feb 2015 | A1 |
20150057901 | Sundholm et al. | Feb 2015 | A1 |
20150073385 | Lyon et al. | Mar 2015 | A1 |
20150087944 | Levinson et al. | Mar 2015 | A1 |
20150136122 | Stuart et al. | May 2015 | A1 |
20150250959 | Stuart et al. | Sep 2015 | A1 |
20150258272 | Sullivan et al. | Sep 2015 | A1 |
20150278476 | Levinson et al. | Oct 2015 | A1 |
20150352295 | Burton et al. | Dec 2015 | A1 |
20160038068 | Chickering, III et al. | Feb 2016 | A1 |
20160051981 | Berthier et al. | Feb 2016 | A1 |
20160067468 | Chowdhury | Mar 2016 | A1 |
20160136365 | Stuart et al. | May 2016 | A1 |
20160144100 | Gharib et al. | May 2016 | A1 |
20160199581 | Cachemaille et al. | Jul 2016 | A1 |
20160213295 | Matsunami et al. | Jul 2016 | A1 |
20160256095 | Krasnow et al. | Sep 2016 | A1 |
20160262676 | Haghgooie et al. | Sep 2016 | A1 |
20160315123 | Kim et al. | Oct 2016 | A1 |
20160324506 | Tariyal et al. | Nov 2016 | A1 |
20160354589 | Kobayashi et al. | Dec 2016 | A1 |
20160361006 | Bullington et al. | Dec 2016 | A1 |
20170001192 | Kelly et al. | Jan 2017 | A1 |
20170014822 | Ker | Jan 2017 | A1 |
20170021067 | Todd et al. | Jan 2017 | A1 |
20170021117 | Howgill | Jan 2017 | A1 |
20170035337 | Wilkinson et al. | Feb 2017 | A1 |
20170035975 | Myung et al. | Feb 2017 | A1 |
20170043103 | Wotton et al. | Feb 2017 | A1 |
20170059304 | Ma et al. | Mar 2017 | A1 |
20170120022 | Chickering, III et al. | May 2017 | A1 |
20170122846 | Holmes et al. | May 2017 | A1 |
20170127991 | Bernstein et al. | May 2017 | A1 |
20170173288 | Stam et al. | Jun 2017 | A1 |
20170197029 | Cindrich et al. | Jul 2017 | A1 |
20170224912 | Yodfat et al. | Aug 2017 | A1 |
20170231543 | Cunningham et al. | Aug 2017 | A1 |
20170290977 | Schauderna et al. | Oct 2017 | A1 |
20180001029 | Egeland et al. | Jan 2018 | A1 |
20180008183 | Chickering, III et al. | Jan 2018 | A1 |
20180008703 | Johnson | Jan 2018 | A1 |
20180008808 | Chowdhury | Jan 2018 | A1 |
20180021559 | Xu | Jan 2018 | A1 |
20180078241 | Moga et al. | Mar 2018 | A1 |
20180103884 | Delamarche et al. | Apr 2018 | A1 |
20180126058 | David et al. | May 2018 | A1 |
20180132515 | Lawrence et al. | May 2018 | A1 |
20180132774 | Gonzalez-Zugasti et al. | May 2018 | A1 |
20180242890 | Chickering, III et al. | Aug 2018 | A1 |
20180243543 | Baek et al. | Aug 2018 | A1 |
20180296148 | Gelfand et al. | Oct 2018 | A1 |
20180344631 | Zhang et al. | Dec 2018 | A1 |
20180369512 | Blatchford et al. | Dec 2018 | A1 |
20190000365 | Beyerlein et al. | Jan 2019 | A1 |
20190001076 | Solomon et al. | Jan 2019 | A1 |
20190001081 | Guion et al. | Jan 2019 | A1 |
20190001085 | Cottenden et al. | Jan 2019 | A1 |
20190015584 | Meehan et al. | Jan 2019 | A1 |
20190015827 | Berthier et al. | Jan 2019 | A1 |
20190022339 | Richardson et al. | Jan 2019 | A1 |
20190023473 | Schott | Jan 2019 | A1 |
20190030260 | Wotton et al. | Jan 2019 | A1 |
20190053740 | Bernstein et al. | Feb 2019 | A1 |
20190054010 | Slowey et al. | Feb 2019 | A1 |
20190142318 | Diebold et al. | May 2019 | A1 |
20190159709 | Barone et al. | May 2019 | A1 |
20190209820 | Chickering, III et al. | Jul 2019 | A1 |
20190240470 | Frederickson et al. | Aug 2019 | A1 |
20190298943 | Stuart et al. | Oct 2019 | A1 |
20190336058 | Haghgooie et al. | Nov 2019 | A1 |
20190366067 | Ginggen et al. | Dec 2019 | A1 |
20200009364 | Amir | Jan 2020 | A1 |
20200010219 | Felippone et al. | Jan 2020 | A1 |
20200011860 | Nawana et al. | Jan 2020 | A1 |
20200033008 | Baker | Jan 2020 | A1 |
20200069897 | Hodson et al. | Mar 2020 | A1 |
20200085414 | Berthier et al. | Mar 2020 | A1 |
20200101219 | Wang et al. | Apr 2020 | A1 |
20200147209 | Johnson | May 2020 | A1 |
20200163603 | Jordan et al. | May 2020 | A1 |
20200164359 | Jordan et al. | May 2020 | A1 |
20200246560 | Hodson et al. | Aug 2020 | A1 |
20200253521 | Ivosevic et al. | Aug 2020 | A1 |
20200261668 | Hodson et al. | Aug 2020 | A1 |
20200289808 | Moeckly et al. | Sep 2020 | A1 |
20200297945 | Cottenden et al. | Sep 2020 | A1 |
20200353155 | Bernstein et al. | Nov 2020 | A1 |
20210022681 | Chickering, III et al. | Jan 2021 | A1 |
20210030975 | Burton et al. | Feb 2021 | A1 |
20210059588 | Welch et al. | Mar 2021 | A1 |
20210100487 | Cho et al. | Apr 2021 | A1 |
20210121110 | Kelly et al. | Apr 2021 | A1 |
20210170153 | Ross et al. | Jun 2021 | A1 |
20210196567 | Baker et al. | Jul 2021 | A1 |
20210228124 | Gonzalez-Zugasti et al. | Jul 2021 | A1 |
20210259599 | Haghgooie et al. | Aug 2021 | A1 |
20210298679 | Pierart | Sep 2021 | A1 |
20210330227 | Levinson et al. | Oct 2021 | A1 |
20210369150 | Bernstein et al. | Dec 2021 | A1 |
20210378567 | Weidemaier et al. | Dec 2021 | A1 |
20220031211 | Yakhnich et al. | Feb 2022 | A1 |
20220058895 | Han | Feb 2022 | A1 |
20220062607 | Davis et al. | Mar 2022 | A1 |
20220071534 | Gonzalez-Zugasti et al. | Mar 2022 | A9 |
20220133192 | Brancazio | May 2022 | A1 |
20220134072 | Kosel et al. | May 2022 | A1 |
20220215921 | Levinson et al. | Jul 2022 | A1 |
20220218251 | Jackson et al. | Jul 2022 | A1 |
20220233117 | Lee et al. | Jul 2022 | A1 |
20220249818 | Chickering, III et al. | Aug 2022 | A1 |
20220257158 | Haghgooie et al. | Aug 2022 | A1 |
20220287642 | Chickering, III et al. | Sep 2022 | A1 |
20220313128 | Bernstein et al. | Oct 2022 | A1 |
20220330860 | Nawana | Oct 2022 | A1 |
20220361784 | Jordan et al. | Nov 2022 | A1 |
20230109881 | Nawana et al. | Apr 2023 | A1 |
Number | Date | Country |
---|---|---|
2006283345 | Mar 2007 | AU |
2016266112 | Dec 2016 | AU |
101296752 | Oct 2008 | CN |
0931507 | Jul 1999 | EP |
1769735 | Apr 2007 | EP |
2493537 | Sep 2012 | EP |
3513833 | Jul 2019 | EP |
3490453 | Dec 2021 | EP |
3962363 | Mar 2022 | EP |
2550668 | Nov 2015 | ES |
2565805 | Apr 2016 | ES |
1492500 | Nov 1977 | GB |
2004024164 | Jan 2004 | JP |
101857300 | May 2018 | KR |
9311747 | Jun 1993 | WO |
9929296 | Jun 1999 | WO |
0078286 | Dec 2000 | WO |
0210037 | Feb 2002 | WO |
0226217 | Apr 2002 | WO |
0232785 | Apr 2002 | WO |
02083205 | Oct 2002 | WO |
02083231 | Oct 2002 | WO |
02083232 | Oct 2002 | WO |
03002069 | Jan 2003 | WO |
03030880 | Apr 2003 | WO |
03035510 | May 2003 | WO |
03066126 | Aug 2003 | WO |
03084597 | Oct 2003 | WO |
03086349 | Oct 2003 | WO |
03086350 | Oct 2003 | WO |
03089036 | Oct 2003 | WO |
2004009172 | Jan 2004 | WO |
2004022133 | Mar 2004 | WO |
2004022142 | Mar 2004 | WO |
2004032990 | Apr 2004 | WO |
2004039429 | May 2004 | WO |
2004062715 | Oct 2004 | WO |
2004098576 | Nov 2004 | WO |
2005006535 | Jan 2005 | WO |
2005026236 | Mar 2005 | WO |
2005060441 | Jul 2005 | WO |
2005014078 | Oct 2005 | WO |
2005084534 | Oct 2005 | WO |
2005123173 | Dec 2005 | WO |
2006016364 | Feb 2006 | WO |
2006055795 | May 2006 | WO |
2006055799 | May 2006 | WO |
2006055802 | May 2006 | WO |
2006055844 | May 2006 | WO |
2006062848 | Jun 2006 | WO |
2006062974 | Jun 2006 | WO |
2006108185 | Oct 2006 | WO |
2006115663 | Nov 2006 | WO |
2006135696 | Dec 2006 | WO |
2007002521 | Jan 2007 | WO |
2007002522 | Jan 2007 | WO |
2007002523 | Jan 2007 | WO |
2007023276 | Mar 2007 | WO |
2007061781 | May 2007 | WO |
2007064486 | Jun 2007 | WO |
2007103712 | Sep 2007 | WO |
2006110723 | Nov 2007 | WO |
2007124411 | Nov 2007 | WO |
2008014161 | Jan 2008 | WO |
2007124406 | Feb 2008 | WO |
2008008845 | Apr 2008 | WO |
2008049107 | Apr 2008 | WO |
2008091602 | Sep 2008 | WO |
2008121459 | Oct 2008 | WO |
2008149333 | Jan 2009 | WO |
2009037192 | Mar 2009 | WO |
2009046173 | May 2009 | WO |
2009061895 | May 2009 | WO |
2009061907 | May 2009 | WO |
2009056981 | Aug 2009 | WO |
2009126653 | Oct 2009 | WO |
2009158300 | Dec 2009 | WO |
2009142852 | Jan 2010 | WO |
2010049048 | May 2010 | WO |
2010059605 | May 2010 | WO |
2010062908 | Jun 2010 | WO |
2010071262 | Jun 2010 | WO |
2010098339 | Sep 2010 | WO |
2010101621 | Sep 2010 | WO |
2010101625 | Sep 2010 | WO |
2010101626 | Sep 2010 | WO |
2010101620 | Nov 2010 | WO |
2010129783 | Nov 2010 | WO |
2010002613 | Dec 2010 | WO |
2010110916 | Dec 2010 | WO |
2010151329 | Dec 2010 | WO |
2010117602 | Mar 2011 | WO |
2011016615 | Apr 2011 | WO |
2011053787 | May 2011 | WO |
2011053788 | May 2011 | WO |
2011053796 | May 2011 | WO |
2011063067 | May 2011 | WO |
2011065972 | Jun 2011 | WO |
2011071788 | Jun 2011 | WO |
2011075099 | Jun 2011 | WO |
2011075103 | Jun 2011 | WO |
2011075104 | Jun 2011 | WO |
2011075105 | Jun 2011 | WO |
2011075569 | Jun 2011 | WO |
2011084316 | Jul 2011 | WO |
2011088211 | Jul 2011 | WO |
2011094573 | Aug 2011 | WO |
2011014514 | Sep 2011 | WO |
2011088214 | Sep 2011 | WO |
2011113114 | Sep 2011 | WO |
2011116388 | Sep 2011 | WO |
2011084951 | Nov 2011 | WO |
2011088211 | Dec 2011 | WO |
2011150144 | Dec 2011 | WO |
2011163347 | Dec 2011 | WO |
2012030316 | Mar 2012 | WO |
2012018486 | Apr 2012 | WO |
2012045561 | Apr 2012 | WO |
2012048388 | Apr 2012 | WO |
2012049155 | Apr 2012 | WO |
2012054592 | Apr 2012 | WO |
2012021792 | May 2012 | WO |
2012028675 | May 2012 | WO |
2012061556 | May 2012 | WO |
2012089627 | Jul 2012 | WO |
2012122162 | Sep 2012 | WO |
2012145665 | Oct 2012 | WO |
2012117302 | Nov 2012 | WO |
2012149126 | Nov 2012 | WO |
2012149143 | Nov 2012 | WO |
2012154362 | Dec 2012 | WO |
2012173971 | Dec 2012 | WO |
2012149134 | Jan 2013 | WO |
2012149155 | Mar 2013 | WO |
2013036602 | Mar 2013 | WO |
2013050701 | Apr 2013 | WO |
2013055638 | Apr 2013 | WO |
2013055641 | Apr 2013 | WO |
2013059409 | Apr 2013 | WO |
2013082418 | Jun 2013 | WO |
2013082427 | Jun 2013 | WO |
2013090353 | Jun 2013 | WO |
2013096026 | Jun 2013 | WO |
2013096027 | Jun 2013 | WO |
2013112877 | Aug 2013 | WO |
2013120665 | Aug 2013 | WO |
2013136176 | Sep 2013 | WO |
2013136185 | Nov 2013 | WO |
2013165715 | Nov 2013 | WO |
2013188609 | Dec 2013 | WO |
2014004462 | Jan 2014 | WO |
2014018558 | Jan 2014 | WO |
2014039367 | Mar 2014 | WO |
2014052263 | Apr 2014 | WO |
2014058746 | Apr 2014 | WO |
2014059104 | Apr 2014 | WO |
2014078545 | May 2014 | WO |
2014081746 | May 2014 | WO |
2014099404 | Jun 2014 | WO |
2014105458 | Jul 2014 | WO |
2014110016 | Jul 2014 | WO |
2014096001 | Aug 2014 | WO |
2014132239 | Sep 2014 | WO |
2014132240 | Sep 2014 | WO |
2014153447 | Sep 2014 | WO |
2014160804 | Oct 2014 | WO |
2014193725 | Dec 2014 | WO |
2014193727 | Dec 2014 | WO |
2014193729 | Dec 2014 | WO |
2014204951 | Dec 2014 | WO |
2014186263 | Jan 2015 | WO |
2015006292 | Jan 2015 | WO |
2015009523 | Jan 2015 | WO |
2015009530 | Jan 2015 | WO |
2015009531 | Jan 2015 | WO |
2015031552 | Mar 2015 | WO |
2015034709 | Mar 2015 | WO |
2015038556 | Mar 2015 | WO |
2015023649 | Apr 2015 | WO |
2015072924 | May 2015 | WO |
2015116625 | Aug 2015 | WO |
2015153570 | Oct 2015 | WO |
2015153624 | Oct 2015 | WO |
2015168210 | Nov 2015 | WO |
2015168215 | Nov 2015 | WO |
2015168217 | Nov 2015 | WO |
2015179511 | Nov 2015 | WO |
2016009986 | Jan 2016 | WO |
2016018892 | Feb 2016 | WO |
2016081843 | May 2016 | WO |
2016099986 | Jun 2016 | WO |
2016100708 | Jun 2016 | WO |
2016109336 | Jul 2016 | WO |
2016109339 | Jul 2016 | WO |
2016109342 | Jul 2016 | WO |
2016118459 | Jul 2016 | WO |
2016122915 | Aug 2016 | WO |
2016132368 | Aug 2016 | WO |
2016137853 | Sep 2016 | WO |
2016164508 | Oct 2016 | WO |
2015168219 | Dec 2016 | WO |
2017044887 | Mar 2017 | WO |
2017062727 | Apr 2017 | WO |
2017062922 | Apr 2017 | WO |
2017075018 | May 2017 | WO |
2017075586 | May 2017 | WO |
2017087355 | May 2017 | WO |
2017087368 | May 2017 | WO |
2017112400 | Jun 2017 | WO |
2017112451 | Jun 2017 | WO |
2017112452 | Jun 2017 | WO |
2017112748 | Jun 2017 | WO |
2017113011 | Jul 2017 | WO |
2017139084 | Aug 2017 | WO |
2017112476 | Sep 2017 | WO |
2017176693 | Oct 2017 | WO |
2017176704 | Oct 2017 | WO |
2017193076 | Nov 2017 | WO |
2018022535 | Feb 2018 | WO |
2018048786 | Mar 2018 | WO |
2018048790 | Mar 2018 | WO |
2018048795 | Mar 2018 | WO |
2018048797 | Mar 2018 | WO |
2018057760 | Mar 2018 | WO |
2018128976 | Jul 2018 | WO |
2018132515 | Jul 2018 | WO |
2018204217 | Nov 2018 | WO |
2018213244 | Nov 2018 | WO |
2019067567 | Apr 2019 | WO |
2019121324 | Jun 2019 | WO |
2020025823 | Feb 2020 | WO |
2020102281 | May 2020 | WO |
2020223710 | Nov 2020 | WO |
2021007344 | Jan 2021 | WO |
2021041881 | Mar 2021 | WO |
2021076846 | Apr 2021 | WO |
2021121638 | Jun 2021 | WO |
2021198768 | Oct 2021 | WO |
2021222066 | Nov 2021 | WO |
2021222805 | Nov 2021 | WO |
2022064055 | Mar 2022 | WO |
Entry |
---|
U.S. Appl. No. 17/412,205, filed Aug. 25, 2021, Namal Nawana. |
U.S. Appl. No. 17/412,213, filed Aug. 25, 2021, Namal Nawana. |
U.S. Appl. No. 17/521,466, filed Nov. 8, 2021, Namal Nawana. |
International Search Report and Written Opinion, PCT/US2022/024607, dated Aug. 4, 2022, 17 pages. |
English machine translation of JP-2004024164-A, patents.google.com, 8 pages. |
International Search Report and Written Opinion, PCT/US2022/029829, dated Nov. 23, 2022, 16 pages. |
International Search Report and Written Opinion, PCT/US2022/046384, dated Jan. 5, 2023, 12 pages. |
International Search Report and Written Opinion, PCT/US2022/048913, dated Feb. 21, 2023, 16 pages. |
Taiwan Office Action, TW111142334, dated May 18, 2023, 15 pages. |
International Preliminary Report on Patentability for International Application No. PCT/US2022/024607 dated Oct. 12, 2023. |
International Search Report and Written Opinion for PCT/US2022/046384 dated Jan. 5, 2023. |
Written Opinion for International Application No. PCT/US2022/024607 dated Oct. 12, 2023. |
Number | Date | Country | |
---|---|---|---|
20230109881 A1 | Apr 2023 | US |